{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004063","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.490652+00:00","generated_at":"2026-05-28T05:16:26.147492+00:00","sec_items":["2.02","5.02","8.01","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Spero Therapeutics receives SEC Wells Notice; CEO placed on paid administrative leave","bullets":["SEC staff preliminarily recommends enforcement action over 2022 disclosures on tebipenem HBr commercialization.","CEO Satyavrat Shukla agrees to paid administrative leave; CFO Esther Rajavelu appointed interim CEO.","Director Frank Thomas replaces Dr. Ankit Mahadevia as Chairman of the Board.","Preliminary cash and equivalents of $52.9M as of Dec 31, 2024; runway into mid-2026.","Phase 3 PIVOT-PO trial enrollment exceeds 60%; on track for full enrollment in 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004063","json":"https://secwatch.observer/filing/0001193125-25-004063.json","markdown":"https://secwatch.observer/filing/0001193125-25-004063.md","text":"https://secwatch.observer/filing/0001193125-25-004063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525004063/0001193125-25-004063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525004063/d820907d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:16:26.147492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}